14 reports of this reaction
1.7% of all HYDROGEN PEROXIDE reports
#9 most reported adverse reaction
SHOCK HAEMORRHAGIC is the #9 most commonly reported adverse reaction for HYDROGEN PEROXIDE, manufactured by Rowpar Pharmaceuticals, Inc.. There are 14 FDA adverse event reports linking HYDROGEN PEROXIDE to SHOCK HAEMORRHAGIC. This represents approximately 1.7% of all 808 adverse event reports for this drug.
Patients taking HYDROGEN PEROXIDE who experience shock haemorrhagic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SHOCK HAEMORRHAGIC is a less commonly reported adverse event for HYDROGEN PEROXIDE, but still significant enough to appear in the safety profile.
In addition to shock haemorrhagic, the following adverse reactions have been reported for HYDROGEN PEROXIDE:
SHOCK HAEMORRHAGIC has been reported as an adverse event in 14 FDA reports for HYDROGEN PEROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SHOCK HAEMORRHAGIC accounts for approximately 1.7% of all adverse event reports for HYDROGEN PEROXIDE, making it a notable side effect.
If you experience shock haemorrhagic while taking HYDROGEN PEROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.